(Q37836967)

24 August 2017

1 reference

title

Current approaches to the management of highly sensitized kidney transplant patients (English)

1 reference

24 August 2017

C Süsal

1

1 reference

24 August 2017

C Morath

series ordinal

2

1 reference

24 August 2017

publication date

1 March 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

77

1 reference

24 August 2017

issue

3

1 reference

24 August 2017

page(s)

177-186

1 reference

HLA antibodies and the occurrence of early adverse events in the modern era of transplantation: a collaborative transplant study report

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2011.01638.X

Almost all patients who are waiting for a regraft of a kidney transplant have anti-HLA antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2011.01638.X

A lifetime versus a graft life approach redefines the importance of HLA matching in kidney transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2011.01638.X

Presensitized kidney graft recipients with HLA class I and II antibodies are at increased risk for graft failure: a Collaborative Transplant Study report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2011.01638.X

Detection of anti-MICA antibodies in patients awaiting kidney transplantation, during the post-transplant course, and in eluates from rejected kidney allografts by Luminex flow cytometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2011.01638.X

Multicenter evaluation of a novel endothelial cell crossmatch test in kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2011.01638.X

An Integrative Approach for the Transplantation of High-Risk Sensitized Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2011.01638.X

Renal transplantation across HLA and ABO antibody barriers: integrating paired donation into desensitization protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2011.01638.X

Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2011.01638.X

Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2011.01638.X

A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2011.01638.X

Successful deceased-donor kidney transplantation in crossmatch-positive patients with peritransplant plasma exchange and Rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2011.01638.X

Peritransplant immunoadsorption for positive crossmatch deceased donor kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2011.01638.X

Mechanisms of alloantibody production in sensitized renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2011.01638.X

Rituximab and intravenous immune globulin for desensitization during renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2011.01638.X

Presensitization: the problem and its management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2011.01638.X

Peri-operative immunoadsorption in sensitized renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2011.01638.X

Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2011.01638.X

Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2011.01638.X

Effect of the proteasome inhibitor bortezomib on humoral immunity in two presensitized renal transplant candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2011.01638.X

Dampening Ab responses using proteasome inhibitors following in vivo B cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2011.01638.X

The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2011.01638.X

ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2011.01638.X

Significance of the positive crossmatch test in kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2011.01638.X

Pretransplant donor-specific antibodies in cytotoxic negative crossmatch kidney transplants: are they relevant?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2011.01638.X

Plasma exchange and immunoadsorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2011.01638.X

Chronic allograft nephropathy: current concepts and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2011.01638.X

Humoral theory of transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2011.01638.X

Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2011.01638.X

Infection in solid-organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2011.01638.X

American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2011.01638.X

Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2011.01638.X

Living donor kidney transplantation across positive crossmatch: the University of Illinois at Chicago experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2011.01638.X

Positive cross-match living donor kidney transplantation: longer-term outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2011.01638.X

10.1111/J.1399-0039.2011.01638.X

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference